隨著國內的降價政策趨緩,藥企逐漸適應醫保談判,一些有潛在全球領先或同類最佳的公司,值得看高一綫。

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Like